Intra-Cellular Therapies Stock Price, News & Analysis

Intra-Cellular Therapies (Nasdaq: ITCI) has announced that its CEO, Sharon Mates, Ph.D., will present at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 11:45 a.m. ET. This event will be available as a live and archived webcast, accessible via the Events & Presentations section of their website. Attendees are advised to log in 5-10 minutes early to register and install any necessary software.

Founded on Nobel prize-winning research, Intra-Cellular Therapies focuses on developing therapeutics for complex psychiatric and neurologic diseases. Their innovative approach targets the inner workings of cells to create effective treatments. For more details, visit www.intracellulartherapies.com.

Intra-Cellular Therapies (ITCI) announced positive topline results from Study 403 for lumateperone 42mg, showing significant efficacy in reducing symptoms of major depressive episodes in patients with mixed features of major depressive disorder (MDD) and bipolar depression. Lumateperone demonstrated a 5.7-5.9 point reduction in scores on the Montgomery Asberg Depression Rating Scale (MADRS) compared to placebo (p<0.0001). Key secondary endpoints also showed significant improvement on the Global Impression of Severity Scale (CGI-S). The treatment was well tolerated with consistent safety profiles. A conference call is scheduled to discuss results and next steps with the FDA.

Intra-Cellular Therapies (Nasdaq: ITCI) reported a remarkable financial performance for full year 2022, with total revenues of $250.3 million, a significant increase from $83.8 million in 2021. CAPLYTA’s fourth quarter net product sales surged to $87.4 million, marking a 243% year-over-year growth. The company anticipates CAPLYTA 2023 net product sales between $430 million and $455 million. Despite substantial growth, the net loss for 2022 was $256.3 million, down from $284.1 million in 2021, highlighting the company's ongoing investments in commercialization and R&D.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced a conference call on March 1, 2023, at 8:30 a.m. ET to discuss its financial results for the quarter and year ending December 31, 2022. The call will provide a corporate update and details of the company’s performance. Participants must register in advance through a provided link to access the live call, with an archived webcast available on the company's Investor Relations website. Intra-Cellular Therapies focuses on developing therapeutics for central nervous system disorders, leveraging innovative research methodologies.

Intra-Cellular Therapies (Nasdaq: ITCI) has announced that its CEO, Sharon Mates, Ph.D., will present at the SVB Securities Global Biopharma Conference on February 15, 2023, at 10:40 a.m. ET. The conference aims to showcase innovations in biopharmaceuticals, with a focus on therapies for central nervous system disorders.

Participants can access the live and archived webcast through the Investor Relations section of the company's website. Intra-Cellular Therapies specializes in developing treatments for complex psychiatric and neurologic diseases, leveraging Nobel prize-winning research.

Intra-Cellular Therapies (Nasdaq: ITCI) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 11:15 a.m. PT, according to a recent announcement. The presentation will be led by Sharon Mates, Ph.D., CEO and Chairman of the company. Interested attendees can access the live and archived webcast on the company's Investor Relations webpage. Intra-Cellular Therapies focuses on developing innovative treatments for central nervous system disorders, based on Nobel prize-winning research.

Intra-Cellular Therapies (Nasdaq: ITCI) presented new findings at the ACNP 61st Annual Meeting, showcasing the efficacy and safety of CAPLYTA (lumateperone) for treating bipolar I and II depression. The analysis involved over 1,200 patients, confirming CAPLYTA's favorable cardiometabolic profile with no significant weight gain. Efficacy results indicated significant improvement in depression symptoms compared to placebo. Additionally, CAPLYTA demonstrated a low incidence of treatment-emergent mania and extrapyramidal symptoms. CAPLYTA is approved for schizophrenia and bipolar depression treatment.

Intra-Cellular Therapies (Nasdaq: ITCI) will participate in two investor conferences, aimed at advancing its focus on treatments for central nervous system disorders. The J.P. Morgan Equity Opportunities Forum takes place from November 14-15, 2022, in Miami, FL. Following this, the company will be featured at the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 29, 2022, at 12:35 PM ET. Interested investors can access a live webcast of the fireside chat by visiting the company's website.

Intra-Cellular Therapies reported net product revenues of $71.9 million for Q3 2022, a 233% increase from Q3 2021. Total revenues rose to $71.9 million from $22.2 million year-on-year. While total prescriptions for CAPLYTA surged 220% year-over-year, net loss narrowed to $53.5 million compared to $76.9 million in Q3 2021. Cash reserves stood at $630.5 million as of September 30, 2022, bolstered by a $460 million public offering in January 2022. CAPLYTA's expansion into bipolar depression is ongoing, supported by new dosage strengths.